Pharma Equity Group appoints new CEO and restructures for long-term shareholder value

From GlobeNewswire: 2025-02-28 06:56:21

Pharma Equity Group A/S has announced Christian Henrik Tange as their new CEO, effective April 1, 2024. Tange brings over 25 years of financial transformation experience to the role. Current CEO, Thomas Kaas Selsø, will resign in March 2025, focusing on consulting. Tange’s international experience includes raising capital and M&A transactions. The Board of Directors is optimistic about Tange’s impact on the company’s growth. In a strategic move, Sebastian Bo Jakobsen has been appointed CEO of subsidiary Reponex Pharmaceuticals A/S. The restructuring aims to enhance focus on clinical development and strategic collaborations, ensuring long-term value for shareholders.



Read more at GlobeNewswire: Change of executive management and organizational change in